Denali Growth Partners Research
Investment Thesis
Denali Growth Partners (DGP) is a Boston-based growth equity firm founded in 2021 by Jesse Lane, formerly of Summit Partners. The firm's core thesis is partnering with exceptional entrepreneurs building growing, profitable, and capital-efficient businesses in healthcare, technology, and services. DGP seeks to accelerate growth for companies that have achieved meaningful scale but need strategic capital and operational support to reach their next phase. The firm emphasizes deep alignment with founders and provides both capital and value-add through its Executive Network of 30+ healthcare and technology executives — individuals who have built exceptional organizations across DGP's focus sectors and remain available to portfolio companies.
DGP explicitly targets companies that are:
- Founder-led or entrepreneur-led with strong management teams
- Demonstrably growing with capital efficiency and a path to profitability
- Positioned for high-impact growth with additional resources and relationships
- Operating in healthcare, life sciences, technology, or tech-enabled services
Stage Focus
DGP focuses exclusively on growth equity investments — companies that have moved beyond the early venture stage and are generating meaningful revenue. Portfolio stage history spans Series A through late-stage growth equity, with deal sizes typically ranging from $10M to $100M per investment. They do not invest in pre-revenue or early-stage startups.
Check Size
DGP typically invests between $10 million and $100 million per investment, as explicitly stated in their October 2025 press materials. With total AUM of approximately $750 million as of January 2026, the firm concentrates in the lower-to-middle end of growth equity with meaningful ownership positions in each portfolio company.
Lead Tendency
DGP frequently leads or co-leads investment rounds, though they also participate in syndicated deals alongside other growth equity firms. Notable examples include:
- Led Luxonis $14M Series A (July 2026) with co-investor Taiwania Capital
- Co-led HiLabs $39M Series B alongside Eight Roads Ventures (March 2024)
- Co-led Tobin Scientific $65M round alongside Truck 9 Partners (May 2025)
- Co-led NationsBenefits $170M round alongside The Pritzker Organization (August 2021)
- Participated in MD Integrations $77M round alongside Updata Partners (October 2025)
Sector Focus
DGP's investment focus is organized around three core verticals:
Healthcare IT and Digital Health
- AI-powered healthcare data management and analytics (HiLabs)
- AI-enabled behavioral science and insights for biopharma (BEESY)
- Telehealth platforms and virtual care infrastructure (MD Integrations, Sollis Health)
- Supplemental benefits technology for Medicare Advantage (NationsBenefits)
Life Sciences Services and Infrastructure
- Outsourced IT and technology consulting for pharma/biopharma (Slipstream IT)
- cGMP cold chain storage, biorepository services, and logistics (Tobin Scientific)
Healthcare Services
- Veterinary care (Boston Veterinary Clinic)
Emerging Technology (Expanding Focus)
- Spatial AI and robotic vision infrastructure (Luxonis — a notable expansion into deep tech/robotics AI)
Geographic Focus
DGP is US-focused. All known portfolio companies are headquartered and primarily operating in the United States. The firm is headquartered at 545 Boylston Street, Suite 1101, Boston, MA 02116.
Fund Status and Recent Activity
DGP has been actively deploying capital from Fund II ($400M, final close May 2025):
- July 2026: Led Luxonis $14M Series A (spatial AI for physical AI and robotics, Denver, CO)
- February 2026: Minority growth investment in BEESY (AI behavioral science market research for biopharma)
- October 2025: Co-invested in MD Integrations $77M round (telehealth infrastructure platform)
- August 2025: Participated in Slipstream IT's new round alongside new co-investor GreyLion Partners
- May 2025: Co-led Tobin Scientific $65M investment (life sciences cold chain logistics)
Fund I: Inaugural fund of approximately $203M (2021) Fund II: $400M final close (May 2025) Total RAUM: $750M+ as of January 1, 2026
Portfolio Highlights
- Luxonis (Jul 2026, Series A, $14M): Denver-based spatial AI company that makes the perception hardware and software enabling physical AI and robotic vision. DGP led this round with Taiwania Capital.
- BEESY (Feb 2026): AI-enabled behavioral science market research, insights, and technology firm for the commercial biopharmaceutical market. Works with 6 of the top 10 global pharmaceutical companies.
- MD Integrations (Oct 2025, $77M): The only unified telehealth platform built on a nationwide, doctor-only network. Delivered millions of patient consults across all 50 states. Co-invested alongside Updata Partners.
- Slipstream IT (portfolio since 2022, follow-on Aug 2025): Trusted technology consulting partner exclusively serving the pharmaceutical and biopharmaceutical industry. Jesse Lane described Slipstream as "a scalable, growing, and resilient business."
- Tobin Scientific (May 2025, $65M): Leading provider of cGMP storage, biorepository services, and specialized logistics for life sciences. Over 365,000 sq ft of cold chain and ambient warehouse space.
- HiLabs (Mar 2024, $39M Series B): AI-powered data management platform (MCheck) for healthcare payers and providers. Cleans and enriches healthcare data for four of the nation's top ten health payers.
- NationsBenefits (Aug 2021, $170M co-lead): Technology company serving Medicare Advantage supplemental benefits. Later received additional investment from General Atlantic.
- Sollis Health (Jan 2022, $30M Series A): Concierge medical care provider.
- Boston Veterinary Clinic (May 2022, Series A): Boston's leading family veterinary clinic network; Fear Free certified.
Team
- Jesse Lane, Founder / Managing Partner: Founded DGP in 2021. Previously growth equity investor at Summit Partners, focused on technology, healthcare, and life sciences. Harvard AB; Stanford Graduate School of Business MBA.
- Bill Stuart, COO / Operating Partner: Diverse operating experience across growth-stage technology and healthcare companies. Previously served as CFO, COO, and CEO of multiple companies; managed early commercialization of medical device companies. Case Western Reserve BS (Mechanical Engineering); Weatherhead School of Management MBA.
- Dave Prendergast, Principal: Previously Principal at Enhanced Healthcare Partners (growth equity in healthcare IT and services). Earlier roles at Waud Capital Partners, Great Point Partners, and Summit Partners. Cornell BS; Harvard Business School MBA.
- Alec Douglas, Principal: Previously VP at Silicon Valley Bank, responsible for credit facilities to HCIT and SaaS businesses. University of Richmond BSBA (Finance).
- Ames Lyman, VP Portfolio Operations: Previously Project Leader at Boston Consulting Group focused on PE due diligence, strategy, and value creation across technology, healthcare, and life sciences. Harvard AB; MIT Sloan MBA; Harvard Kennedy School MPA.
- Kyle Daly, Senior Associate: Previously Investment Banking Associate at William Blair (Healthcare Technology group); Analyst at Provident Healthcare Partners. Merrimack College BSBA (Finance).
- Sean Farmer, Associate: Ohio State University Fisher College of Business BS (Finance, summa cum laude).
- Ali Mobtaker, Associate: Member of DGP investment team.
- Aarnav Prakash, Analyst: Member of DGP investment team.
- Andrew Rusis, Analyst: Member of DGP investment team.
- Cameron Spiro, Analyst: Member of DGP investment team.
- Elizabeth Tevis, Analyst: Member of DGP investment team.
- Hung Truong, Fund Controller: Manages fund administration and finance.
Decision Process
DGP operates as a partnership led by Jesse Lane (Founder/Managing Partner). Investment decisions involve the broader investment team. They take both minority and majority investment positions and emphasize founder alignment from day one. DGP noted in multiple press releases that they "get to know" management teams well over multiple years before investing, suggesting a relationship-driven process.
Operational Value-Add
DGP differentiates on operational support:
- Executive Network: 30+ healthcare and technology executives available to portfolio companies; these individuals have built and scaled companies in DGP's focus sectors
- Portfolio Operations: Dedicated VP of Portfolio Operations (Ames Lyman) focused on value creation
- Operating Partner: Bill Stuart as COO/Operating Partner brings direct operating experience as CFO/COO/CEO
Founder Preferences
DGP explicitly seeks exceptional founders who are driven and want a partner providing "more than capital." They value:
- Deep domain expertise and operator backgrounds
- Companies with proven, repeatable revenue growth and capital efficiency
- Management teams committed to building category-defining organizations
- Founders willing to engage deeply with DGP's Executive Network and operational resources
Awards and Recognition
- 2023 Private Equity & Venture Capital Award: Best HealthTech Growth Equity Firm (Wealth & Finance magazine)
- 2023 Private Equity Wire US Emerging Managers Award: Best Performance in Growth Equity